Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.35 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12891724 | 0.78 | CHRNB2 (0.38) | CHRNB2CHRNA4KLKB1GRM5 | |
| SCHEMBL12891722 | 0.78 | CHRNB2 (0.38) | CHRNB2CHRNA4KLKB1GRM5 | |
| SCHEMBL31247610 | 0.76 | CHRNB2 (0.39) | CHRNB2CHRNA4KLKB1P2RX7GRM5 | |
| SCHEMBL868299 | 0.75 | GRM5 (0.52) | CHRNB2CHRNA4GRM5 | |
| SCHEMBL14614599 | 0.75 | CHRNB2 (0.38) | CHRNB2CHRNA4KLKB1P2RX7GRM5 | |
| SCHEMBL29364445 | 0.75 | CHRNB2 (0.38) | CHRNB2CHRNA4KLKB1P2RX7GRM5 | |
| SCHEMBL14614714 | 0.75 | CHRNB2 (0.38) | CHRNB2CHRNA4KLKB1P2RX7GRM5 | |
| SCHEMBL18795872 | 0.75 | CHRNB2 (0.38) | CHRNB2CHRNA4KLKB1P2RX7GRM5 | |
| SCHEMBL868367 | 0.74 | AKR1C3 (0.41) | CHRNB2CHRNA4KLKB1GRM5 | |
| SCHEMBL28931584 | 0.74 | HDAC1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2024-09-17 | — | — | US | disclosed |
| CN-113874371-B | Preparation method of tri-fused ring compound and intermediate thereof | 诺和诺德股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| US-20230052348-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2023-02-16 | — | — | US | disclosed |
| US-20230052348-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2023-02-16 | — | — | US | disclosed |
| CN-115413275-A | Substituted 1,1 , -biphenyl compounds and methods of use thereof | 爱彼特生物制药公司 | 2022-11-29 | — | — | CN | disclosed |
| US-11306107-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2022-04-19 | — | — | US | disclosed |
| US-20210230189-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2021-07-29 | — | — | US | disclosed |
| US-20210230189-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2021-07-29 | — | — | US | disclosed |
| WO-2017147410-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2017-08-31 | — | — | WO | disclosed |
| CN-106660982-A | Histone demethylase inhibitors | 赛尔基因昆蒂赛尔研究公司 | 2017-05-10 | — | — | CN | disclosed |
| CN-101223142-A | Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO KGAA (DE) | 2008-07-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230189-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | CHRNB2 4842/4885CHRNA4 4878/4885KLKB1 4410/4885 |
| US-11306107-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | CHRNB2 4842/4885CHRNA4 4878/4885KLKB1 4410/4885 |
| US-20230052348-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | CHRNB2 4842/4885CHRNA4 4878/4885KLKB1 4410/4885 |
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | CHRNB2 4842/4885CHRNA4 4878/4885KLKB1 4410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.